Breast Cancer Treatment Industry Reviewed in Updated Stakeholder Insights Report Now Available at MarketPublishers.com

31 Oct 2011 • by Natalie Aster
Breast Cancer Treatment Industry Reviewed in Updated Stakeholder Insights Report Now Available at MarketPublishers.com

LONDON – While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.

Updated market research study “Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)” prepared by Datamonitor features a complete analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews. Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010–19 in the seven major pharmaceutical markets are provided. The report also covers a detailed segmentation of incident cases by age group, menopausal status, stage of disease and subtype, and offers an in-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage.

Report Details:

Title: Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)
Published: November, 2010
Pages: 307
Price: US$ 15,200

Reports Contents:

Executive Summary
Scope of the analysis
Datamonitor insight into the hormone receptor-negative breast cancer market
Contributing experts
Related reports
Upcoming related reports

OVERVIEW

Catalyst
Summary

1. INTRODUCTION AND SCOPE

Coverage of the Stakeholder Insight Survey
Epidemiology
Treatment options
Treatment trends
Future treatment

2. EPIDEMIOLOGY

Introduction and background
Key points
Disease definition and diagnosis criteria
Global variation and historical trends
Incidence rates
Prevalence
Risk factors
Reproductive factors
Exogenous hormones
Lifestyle factors
Socioeconomic factors
Genetic predisposition
Epidemiologic forecasting of breast cancer
Sources of epidemiologic data
Categorization and stratification
Description of methods
Statistical analysis
Epidemiologic forecast results
Estimated incident cases and future trends of breast cancer
Segmentation of incident cases: 2010
Estimated prevalent cases
Discussion
US
Japan
Europe
Strengths of our epidemiologic projections
Conclusions

3. DISEASE OVERVIEW

Introduction
Breast cancer is the most common tumor type in females
Anatomy of the breast
Histology of breast cancer
Patient segmentation

More new and updated market research reports by the publisher can be found at Datamonitor page.

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com